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Ghost authorship, the failure to name, as an author, an individual who has made substantial
contributions to an article, may result in lack of accountability. The prevalence and nature of
ghost authorship in industry-initiated randomised trials is not known.
Methods and Findings
We conducted a cohort study comparing protocols and corresponding publications for
industry-initiated trials approved by the Scientific-Ethical Committees for Copenhagen and
Frederiksberg in 1994–1995. We defined ghost authorship as present if individuals who wrote
the trial protocol, performed the statistical analyses, or wrote the manuscript, were not listed as
authors of the publication, or as members of a study group or writing committee, or in an
acknowledgment. We identified 44 industry-initiated trials. We did not find any trial protocol or
publication that stated explicitly that the clinical study report or the manuscript was to be
written or was written by the clinical investigators, and none of the protocols stated that
clinical investigators were to be involved with data analysis. We found evidence of ghost
authorship for 33 trials (75%; 95% confidence interval 60%–87%). The prevalence of ghost
authorship was increased to 91% (40 of 44 articles; 95% confidence interval 78%–98%) when
we included cases where a person qualifying for authorship was acknowledged rather than
appearing as an author. In 31 trials, the ghost authors we identified were statisticians. It is likely
that we have overlooked some ghost authors, as we had very limited information to identify
the possible omission of other individuals who would have qualified as authors.
Conclusions
Ghost authorship in industry-initiated trials is very common. Its prevalence could be
considerably reduced, and transparency improved, if existing guidelines were followed, and if
protocols were publicly available.
The Editors’ Summary of this article follows the references.
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PLoS MEDICINEIntroduction
Authorship establishes accountability, responsibility, and
credit for scientiﬁc articles [1]. If authorship is misappro-
priated, readers may be misled, and the potential for
manipulated analyses and conclusions may increase. One
type of misappropriation is ghost authorship, which has been
deﬁned as the failure to name, as an author, an individual
who has made substantial contributions to the research or
writing of the article [1].
A conﬁdential survey of corresponding authors of research
reports, editorials, reviews, and opinion articles in six medical
journals with 69% response rate showed that 13% of 809
articles had ghost authors [1]. This is likely an underestimate
because of the modest response rate and because those who
responded might be reluctant to admit that ghost authors had
contributed to their paper.
We examined directly the prevalence and nature of ghost
authorship in a cohort of industry-initiated randomised trials
by comparing the trial protocols with subsequent publica-
tions. We have previously documented widespread con-
straints on the publication rights of clinical investigators in
these trials [2].
Methods
For all published industry-initiated randomised trials
approved in 1994–1995 by the Scientiﬁc-Ethical Committees
for Copenhagen and Frederiksberg in Denmark, we com-
pared the full trial protocols with the publications. We
initially identiﬁed 274 approved trial protocols, but after
extensive literature searches in MEDLINE, EMBASE, and the
Cochrane Controlled Trials Register, and a survey of the
trialists in 2003, we found that 172 trials (63%) were never
begun, completed, or published [3]. Of the 102 published
trials, 56 had industry support [3], but in some cases this was
rather minor, such as delivering coded drugs to a trial that
was initiated by academic researchers. Since we wished to
study industry-initiated trials, we excluded 12 such trials that
were initiated by the investigators.
When there was more than one publication for a trial, we
used the one that reported the results for the primary
outcomes, and if no primary outcome was deﬁned, the ﬁrst
publication that reported ﬁnal results. The median publica-
tion year was 1999 (range from 1997 to 2002).
Two observers independently extracted data from each
protocol or publication on name and nationality of the
sponsor; type and location of the trial; and the roles of the
investigators and sponsor in trial design, data collection, data
analysis and interpretation, and manuscript preparation, as
noted anywhere in the text, including separate agreements in
trial protocols as well as footnotes and acknowledgments in
publications using an electronic form. For some items, the
observer could add extracted quotations or write comments.
To reduce redundancy, the second observer was provided
with this additional text. The same observer did not review
both the protocol and the report for the same trial; there was
no other blinding. Disagreements were resolved by discus-
sion.
We deﬁned ghost authorship as present if individuals who
wrote the trial protocol, performed the statistical analyses, or
wrote the manuscript, were not listed as authors of the
publication, or as members of a study group or writing
committee, or in an acknowledgment.
These criteria were an operationalisation of the guidelines
published by the International Committee of Medical Journal
Editors [4], which state that ‘‘an author is someone who has
made substantive intellectual contributions to a published
study.’’ Furthermore, authorship credit should be based on
‘‘(1) substantial contributions to conception and design, or
acquisition of data, or analysis and interpretation of data; (2)
drafting the article or revising it critically for important
intellectual content; and (3) ﬁnal approval of the version to be
published.’’ Authors should meet all three conditions; all
persons designated as authors should qualify for authorship;
and all those who qualify should be listed. These guidelines
are also recommended by The Pharmaceutical Research and
Manufacturers of America [5].
We believe that all who contribute in a major way under
both (1) and (2) should be authors. As it is also likely that some
of those who have only been acknowledged might have
contributed sufﬁciently under either (1) or (2) to have
merited authorship, we did an additional analysis where
people who were acknowledged for having performed the
statistical analyses or having written the protocol or the
manuscript were considered ghost authors.
Results
A total of 44 trials were included, of which 43 (98%) were
initiated by one of 26 multinational pharmaceutical ﬁrms and
one by a local company. Of the total trials, 33 were
multicentre and multinational, two were multicentre Danish
trials, and nine were single-centre trials.
We found evidence of ghost authorship for 31 of the 44
trials (75%; 95% conﬁdence interval 60%–87%) (Table 1). If
individuals who qualiﬁed for authorship, but who were
acknowledged rather than listed as authors, were considered
ghost authors, the prevalence of ghost authorship was 91%
(95% conﬁdence interval 78%–98%). In 31 trials, the ghost
authors we identiﬁed were statisticians. A total of eight
publications acknowledged the assistance of statisticians, and
four acknowledged the assistance of medical writers (Table 1).
It was explicitly stated in 26 protocols that the company
would conduct the statistical analyses or write the clinical
study report or the manuscript. We did not ﬁnd any trial
protocol or publication stating explicitly that the study
report or the manuscript was to be written or was written by
the clinical investigators, and none of the protocols stated
that clinical investigators were to be involved with data
analysis. In three cases, clinicians participated in end-point or
clean ﬁle committees, and in three other cases, clinicians
decided together with the sponsor which data should be
excluded from analysis.
It was also unclear whether clinicians had contributed to the
protocols. None of the trial protocols described explicitly who
had contributed to the design of the trial. In two protocols a
group of clinicians was mentioned who were to advise the
company on protocol design. Only ﬁve protocols explicitly
identiﬁed the author of the protocol, but none of these
individuals—all of whom were company employees—were
listed as authors of the publications or were thanked in the
acknowledgments, although one protocol had noted that the
‘‘author of this protocol will be included in the list of authors.’’
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Ghost AuthorshipA total of 15 reports had named authors and a study group,
and three reports were authored by a study group and
identiﬁed a writing committee. There were three other
reports that had no authors and no writing committee, and
it was therefore not possible to know who of the many
clinicians listed as members of the study group had been
authors. The remaining 21 reports listed the authors in the
byline. Only one publication had a description of contrib-
utorship, and only one a conﬂict of interest statement.
All published reports had clinicians as authors. Company
employees were listed among the authors for 28 (64%) of the
44 publications; there were no such authors for 12 publica-
tions. It was not clear whether some of the authors for the
remaining four reports were company employees as names
were listed without afﬁliations.
Discussion
We found a high prevalence of ghost authorship in
industry-initiated randomised trials. To our knowledge, this
study is the ﬁrst that has systematically examined the
prevalence of ghost authorship using a cohort of protocols
and corresponding publications. We deﬁned ghost author-
ship as present if an individual who wrote the trial protocol,
or performed the statistical analyses, or wrote the manuscript
did not appear among the authors, or members of a study
group or writing committee, or in an acknowledgment. Our
criteria are similar to those used in two previous surveys of
authors [1,6], and by these criteria we found evidence of ghost
authorship in 75% of the articles. In contrast, these two
surveys, which relied on self-reporting, found rates of ghost
authorship of 13% [1] and 11% [6], respectively. The latter
survey addressed 362 Cochrane Reviews; such reviews are a
special case since there is often far more collaboration
between editors and authors than for other articles. Most
commonly, it was a member of the Cochrane editorial team
who was judged to have deserved authorship [6], but it should
be noted that journal editors are generally discouraged from
becoming authors of the manuscripts they edit because of the
obvious conﬂict of interest. We are not aware of other studies
of the prevalence of ghost authorship.
It is a strength of our study that our sample is
representative of all industry-initiated clinical trials, as it
covers a wide range of diseases and specialties, and involves
large multinational companies. Furthermore, the trials were
generally published in well-known peer-reviewed journals
(Table 2), and not in supplements to such journals.
The small sample size is a limitation of our study. Another
limitation is the dates for the protocols, 1994–1995. However,
as the median publication year for all the studies was 1999, it
is not likely that the situation would be much different today.
A number of well-intentioned guidelines have appeared
recently, but we found that constraints on the publication
rights of clinical investigators in protocols for industry-
initiated trials from 2004 were similar to those in protocols
from 1994 to 1995 [2].
It can be questioned whether the main investigator from
the company (two cases) or the main clinical investigator (one
case) should necessarily become authors (Table 1). On the
other hand, it is likely that we have not identiﬁed all ghost
authors, as we had very limited information with which to
identify the possible omission of other individuals who would
have qualiﬁed as authors, other than statisticians. We found
only three publications (7%) that had statisticians among the
authors, in two cases from the company and in the third from
a university, although it was explicitly stated in 26 protocols
that the company conducted the statistical analyses or wrote
the clinical study report or the manuscript. This might have
been the case for all trials, since the companies collected the
data and are obliged by law to submit a report of the results
to the Danish Drug Agency. These ﬁndings are in sharp
contrast to a survey, with a 75% response rate, of 704 authors
of manuscripts submitted to the BMJ and the Annals of Internal
Medicine (only a minority of which were randomised trials),
which found that statisticians and similar methodologists who
had made a signiﬁcant contribution at some stage of the
research process were authors in 86% of the cases [7].
We take issue with this widespread practice of not
including statisticians as authors for reports of randomised
trials. Multicentre trials are often complex and generate large
datasets, and the trials we reviewed were no exception [3].
Furthermore, the statistical report is a fundamental part of
the research that has a crucial inﬂuence on what is written in
the publication. Omission of a company statistician, usually
also from the acknowledgment section, deprives readers of a
key insight into the role of the company, although it is
sometimes evident that reports of industry-sponsored trials
contain sophisticated statistical analyses that are beyond the
capabilities of the authors [8]. We cannot exclude the
possibility that data analyses in some of the trials, and
corresponding sections in protocols, were performed by
company employees who were named authors but not
statisticians, but it is unlikely since the pharmaceutical
Table 1. Ghost Authorship in Trial Reports
Our Conclusion Findings n
Evidence of ghost authorship
(n ¼ 40 trials)
Analyses by company but no







but not listed as author
5
b
Author of protocol not listed as
author of trial report
5
c
Main investigator from company
not listed as author
2
Main clinical investigator not
listed as author
1
Medical writer acknowledged but
not listed as author
1
Unclear (n ¼ 2 trials) No titles for company authors 2
No evidence of ghost authorship
(n ¼ 2 trials)
Company statistician is coauthor 1
Clinicians conducted the analyses,
trial report written by company,
and company authors listed in report
1
Total number of trials (n ¼ 44).
aA main investigator and a company member who participated with the investigators in
the study design, analysis, and manuscript preparation were also missing in one of these
publications each; another statistician was acknowledged in one of these cases.
bA medical writer was also acknowledged in three of these cases; in four cases, it was
likely, but not made explicit, that the statistician was employed by the company.
cA statistician was acknowledged in one case and university statisticians in one case.
doi:10.1371/journal.pmed.00400019.t001
PLoS Medicine | www.plosmedicine.org January 2007 | Volume 4 | Issue 1 | e19 0049
Ghost Authorshipcorporations usually have strong departments of statistics [8].
We believe it is wrong to deny a person who has contributed
substantially (e.g., by performing the statistical analyses and
by writing the statistical report) the opportunity to comment
on the paper and ﬁnally approve of it, thereby fulﬁlling all
three criteria for authors deﬁned by the International
Committee of Medical Journal Editors [4].
A potentially important reason for the missing company
authors could be a change of job, as the median time span
between protocol approval and publication was about ﬁve
years. This should not be a valid reason for the former
company to deny authorship to an individual, but companies
have sometimes denied even their current employees
deserved authorship [9], probably because of the perceived
marketing advantage of papers that appear to have been
written entirely by clinicians. However, if persons who qualify
for authorship decline voluntarily, their contribution should
be acknowledged according to guidelines for editors [4] and
pharmaceutical companies [5,10]. Written permission to be
acknowledged is usually required, however, which might
explain some of the missing acknowledgments.
The guidelines on good publication practices for pharma-
ceutical companies [10] specify that whatever criteria for
authorship are used, they should be applied in the same way
to both external investigators and company employees.
Furthermore, a company’s involvement in data analysis and
preparation of the manuscript should be made clear;
publications should present the results accurately, objec-
tively, and in a balanced fashion; and statisticians should
participate in the preparation of publications. The Interna-
tional Committee of Medical Journal Editors has similar
recommendations but does not give explicit advice on the
role of statisticians [4]. Other guidelines have emphasized the
need to acknowledge the role of medical writers (e.g., those
for the World Association of Medical Editors [11] and
European Medical Writers Association [12]).
For the most part, the current situation does not reﬂect
these recommendations, and there are indications that they
may be difﬁcult to implement. First, legal proceedings and
testimonies suggest that it is very common for professional
medical writers to compose trial reports, reviews, and other
papers for the pharmaceutical industry, but that their role is
not revealed [13–18]. Companies and medical writing
agencies may routinely disguise the fact that papers have
been ghost-written [13], including erasing the ﬁle history of
electronic documents before manuscript submission [19]. We
found no references to medical writers in the protocols we
reviewed, and they were acknowledged in only four publica-
tions (9%), which is consistent with a recent review of
research articles [20]. Second, writing agencies have a vested
interest in pleasing their clients by writing favourably about
the drug in question [13–15,18,21]. Such commercial pres-
sures may explain why conclusions in randomised trials
recommended the experimental drug as the drug of choice
much more often if the trial was funded by for-proﬁt
organisations, even after adjustment for the effect size (odds
ratio 5.3) [22]. Third, honorary (guest) authorship for
clinicians is very common [1,3,6,13,17,21]. Fourth, only six
pharmaceutical companies have endorsed the guidelines for
good publication practice for pharmaceutical companies that
were published in 2003 [23]. In addition, 18 contract research
and communications companies have agreed to recommend
the guidelines to their clients and to follow them in their
work, but such contractors might not be aware of omissions
of qualifying authors and may not be able to convince their
clients to comply.
We conclude that ghost authorship in industry-initiated
randomised trials is very common, and we believe that this
practice serves commercial purposes [13,17,21,22]. Its preva-
lence could be considerably reduced if existing guidelines
were followed; in particular, journals should list the con-
tributions of all authors [24]. In addition, journals could ask
for the name and afﬁliation of the statistician who analysed
the data, if this information is not clear. To improve
transparency and accountability, there is also a need to
specify in protocols who the statisticians and authors will be,
and to make protocols and raw data from trials publicly
available for independent analyses and interpretation
[3,9,13,25]. This practice could increase the likelihood that
publications accurately, fairly, and comprehensively reﬂect
the collected data.
Table 2. List of Journals in which the Results for the Primary
Outcomes from the 44 Trials Were Published
Journals
Acta Obstetricia et Gynecologica Scandinavica
American Journal of Clinical Nutrition
American Journal of Respiratory and Critical Care Medicine
Antimicrobial Agents and Chemotherapy
Arthritis and Rheumatism
Blood
British Journal of Dermatology
British Journal of Haematology









European Journal of Contraception and Reproductive Health Care
European Journal of Vascular and Endovascular Surgery
European Respiratory Journal (two publications)
European Urology
Fertility and Sterility
International Journal of Obesity
Journal of Antimicrobial Chemotherapy
Journal of Clinical Endocrinology and Metabolism
Journal of Clinical Psychiatry (two publications)
Journal of Infectious Diseases
Journal of Neurosurgery
Journal of Psychopharmacology





Pediatric Allergy and Immunology
Pediatrics
Prehospital and Disaster Medicine
Respiratory Medicine
Rheumatology
Scandinavian Journal of Gastroenterology
doi:10.1371/journal.pmed.0040019.t002
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Ghost AuthorshipEditors’ Summary
Background. Original scientific findings are usually published in the
form of a ‘‘paper’’, whether it is actually distributed on paper, or
circulated via the internet, as this one is. Papers are normally prepared by
a group of researchers who did the research and are then listed at the
top of the article. These authors therefore take responsibility for the
integrity of the results and interpretation of them. However, many
people are worried that sometimes the author list on the paper does not
tell the true story of who was involved. In particular, for clinical research,
case histories and previous research has suggested that ‘‘ghost
authorship’’ is commonplace. Ghost authors are people who were
involved in some way in the research study, or writing the paper, but
who have been left off the final author list. This might happen because
the study ‘‘looks’’ more credible if the true authors (for example,
company employees or freelance medical writers) are not revealed. This
practice might hide competing interests that readers should be aware of,
and has therefore been condemned by academics, groups of editors, and
some pharmaceutical companies.
Why Was This Study Done? This group of researchers wanted to get an
idea of how often ghost authorship happened in medical research done
by companies. Previous studies looking into this used surveys, whereby
the researchers would write to one author on each of a group of papers
to ask whether anyone else had been involved in the work but who was
not listed on the paper. These sorts of studies typically underestimate
the rate of ghost authorship, because the main author might not want to
admit what had been going on. However, the researchers here managed
to get access to trial protocols (documents setting out the plans for
future research studies), which gave them a way to investigate ghost
authorship.
What Did the Researchers Do and Find? In order to investigate the
frequency and type of ghost authorship, these researchers identified
every trial which was approved between 1994 and 1995 by the ethics
committees of Copenhagen and Frederiksberg in Denmark. Then they
winnowed this group down to include only the trials that were
sponsored by industry (pharmaceutical companies and others), and only
those trials that were finished and published. The protocols for each trial
were obtained from the ethics committees and the researchers then
matched up each protocol with its corresponding paper. Then, they
compared names which appeared in the protocol against names
appearing on the eventual paper, either on the author list or acknowl-
edged elsewhere in the paper as being involved. The researchers ended
up studying 44 trials. For 31 of these (75% of them) they found some
evidence of ghost authorship, in that people were identified as having
written the protocol or who had been involved in doing statistical
analyses or writing the manuscript, but did not end up listed in the
manuscript. If the definition of authorship was made narrower, and
‘‘ghost authorship’’ included people qualifying for authorship who were
mentioned in the acknowledgements but not the author list, the
researchers’ estimate went up to 91%, that is 40 of the 44 trials. For most
of the trials with missing authors, the ghost was a statistician (the person
who analyzes the trial data).
What Do These Findings Mean? In this study, the researchers found
that ghost authorship was very common in papers published in medical
journals (this study covered a broad range of peer-reviewed journals in
many medical disciplines). The method used in this paper seems more
reliable than using surveys to work out how often ghost authorship
happens. The researchers aimed to define authorship using the policies
set out by a group called the International Committee of Medical Journal
Editors (ICMJE), and the findings here suggest that the ICMJE’s standards
for authorship are very often ignored. This means that people who read
the published paper cannot always accurately judge or trust the
information presented within it, and competing interests may be hidden.
The researchers here suggest that protocols should be made publicly
available so that everyone can see what trials are planned and who is
involved in conducting them. The findings also suggest that journals
should not only list the authors of each paper but describe what each
author has done, so that the published information accurately reflects
what has been carried out.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040019.
  Read the Perspective by Liz Wager, which discusses these findings in
more depth
  The International Committee of Medical Journal Editors (ICMJE) is a
group of general medical journal editors who have produced general
guidelines for biomedical manuscripts; their definition of authorship is
also described
  The Committee on Publication Ethics is a forum for editors of peer-
reviewed journals to discuss issues related to the integrity of the
scientific record; the Web site lists anonymized problems and the
committee’s advice, not just regarding authorship, but other types of
problems as well
  Good Publication Practice for Pharmaceutical Companies outlines
common standards for publication of industry-sponsored medical
research, and some pharmaceutical companies have agreed to these
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